Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis

Inclusion Criteria: * Patients aged 18 or over. * With neurotrophic keratitis at stages 2 or 3 affecting only one eye. * Persistent epithelial defect or corneal ulcer of at least 2 weeks duration resistant to one or more traditional non-surgical treatments . * Corneal sensitivity reduction test in the area of the persistent epithelial defect or corneal ulcer and out of the defect area in at least one corneal quadrant. * No objective clinical evidence of improvement in the two weeks prior to enrollment. * Patients who have previously read and signed the informed consent. Exclusion Criteria: * Patients with neurotrophic keratitis stages 2 or 3 that affects both eyes. * With active ocular infection or inflammation not related to the neurotrophic keratitis * Any other eye disease that requires of topical ocular treatment in the affected eye during study. * Patients with severe vision loss * Patients with severe blepharitis and/or severe Meibomian glands disease * History of eye surgery in the three months prior to enter the study, or patients who plan to undergo surgery. * Having received previously surgical procedures for the treatment of NK. * Use of therapeutic contact lenses or for refractive correction during study. * Patients with punctual occlusion or insertion of punctual plugs previous to the study * Evidence of corneal ulcer affecting the corneal stroma or cornea perforation. * Presence of any disorder or ocular or systemic disease that could limit the treatment effectiveness or its evaluation, * Any need of change (at that time or planned) in the dose of systemic drugs known to disrupt the functioning of the trigeminal nerve * Known hypersensitivity to any of the procedural compounds (eg. fluoresceine). * Presence of blood disorders associated with platelet disorders or clotting, or receiving anticoagulants drugs or antiplatelet agents. * Patients with positive result in one of the serological tests for syphilis, Hepatitis B-C or AIDS I / II. * Patient in current treatment for their pathology already well managed. * Use of any investigational drug within 4 weeks prior to the screening visit. * Pregnant women or intended to be pregnant. * Participating in another clinical trial.